Scynexis (SCYX) Revenue (2013 - 2026)
Scynexis' (SCYX) quarterly Revenue came in at $235000.0 in Q2 2026, down 82.77% on a YoY basis from $1.4 million in Q2 2025, and down 98.74% quarter-over-quarter from $18.6 million in Q4 2025.
Analysis
Scynexis (SCYX) Revenue (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Revenue for 13 consecutive years, with $235000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Revenue fell 82.77% year-over-year to $235000.0; the trailing twelve-month figure through Jun 2026 stood at $19.2 million (up 489.78% YoY), and the FY2025 full-year result was $20.6 million, up 449.95% from the prior year.
- Revenue declined to $235000.0 in Q2 2026 per SCYX's latest filing, from $18.6 million in the prior quarter.
- Across five years, Revenue topped out at $131.5 million in Q2 2023 and bottomed at $235000.0 in Q2 2026.
- Historically, Revenue has averaged $10.0 million across 5 years, with a median of $1.3 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Revenue surged 9836.05% in 2023, then slumped 99.44% in 2024.
- Over 5 years, Revenue stood at $1.5 million in 2022, then surged by 280.38% to $5.8 million in 2023, then tumbled by 83.15% to $977000.0 in 2024, then soared by 1808.5% to $18.6 million in 2025, then tumbled by 98.74% to $235000.0 in 2026.
- According to Business Quant data, Revenue over the past three periods registered $235000.0, $18.6 million, and $334000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Scynexis | 52.73 Mn | -61.96 Mn | - | 235,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 235,000.00 |
| Dec 31, 2025 | 18.65 Mn |
| Sep 30, 2025 | 334,000.00 |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 257,000.00 |
| Dec 31, 2024 | 977,000.00 |
| Sep 30, 2024 | 660,000.00 |
| Jun 30, 2024 | 736,000.00 |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 5.80 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 131.45 Mn |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 1.52 Mn |
| Sep 30, 2022 | 1.56 Mn |
| Jun 30, 2022 | 1.32 Mn |
| Mar 31, 2022 | 700,000.00 |
| Dec 31, 2021 | 597,000.00 |
| Sep 30, 2021 | 516,000.00 |
| Mar 31, 2021 | 12.05 Mn |